| 摘要: |
| 为推动高风险药品生产企业持续符合药品生产质量管理规范,对近三年安徽省开展的高风险药品生产企业依职责GMP符合性检查的缺陷项目进行统计分析。共汇总缺陷项目1 408项,包括严重缺陷7项、主要缺陷88项、一般缺陷1 313项,主要分布于质量控制与质量保证、文件管理、无菌药品附录等方面。高风险药品生产企业应从落实主体责任、强化污染控制策略、建立长效培训机制、严格供应商管理、完善确认与验证、加强产品质量回顾分析等方面着手持续保障药品质量安全。 |
| 关键词: 高风险药品 GMP检查 风险分析 |
| DOI:10.13506/j.cnki.jpr.2024.10.018 |
| 基金项目:盖茨基金项目资助(粉液双室袋产品检查指南课题研究) |
|
出版日期:2024-10-30
|
|
| Risk Analysis and Countermeasures on Responsibility- based GMP Compliance Inspection of High-Risk Drug Manufacturing Enterprises in Anhui Province |
| RUI Xue,YE Liuping,HU Shigao |
| (Anhui Center for Drug Evaluation and Inspection, Hefei 230051,China) |
| Abstract: |
| In order to ensure continued adherence of high-risk drug manufacturing enterprises to GMP, a statistical analysis was performed on the deficiencies identified during the responsibility-based GMP compliance inspections conducted in Anhui Province from 2021 to 2023. A total of 1 408 inspection defects were summarized, including 7 serious defects, 88 major defects and 1 313 general defects, which were mainly in the aspects of quality control and quality assurance, document management, sterile drug appendices, etc. High-risk drugs manufacturing enterprises should implement the main responsibility, strengthen contamination control strategy, establish long-term training mechanism, strictly manage suppliers, improve confirmation and verification and enhance product quality review analysis to continuously improve high-risk drugs quality and safety. |
| Key words: High-risk drug Gmp inspection Risk analysis |